Rinvoq (AbbVie) is expected to face US generic competition from 2037. September 2025 settlements bar US generics before April 2037. Consensus had assumed 2032.
Rinvoq's US exclusivity date is based on settlement / court date. Litigation settlements or a court ruling fix the earliest US entry date, which makes it one of the firmer dates in this tracker. It is a small-molecule drug, so copies are generics. Generic launches usually take most of the US volume within months.
AbbVie settled with every generic filer. Analysts had modeled US exclusivity ending in 2032. Fierce Pharma
Rinvoq is 14% of AbbVie's 2025 revenue ($8.3B of $61.2B). With Skyrizi, the drugs tracked here add up to 42% of AbbVie's revenue losing US exclusivity by 2037.
Bars show each company's tracked drugs as a share of its total 2025 revenue. Rinvoq is highlighted.